August 22, 2012 — A new application of a drug that was approved in 1996 and has been widely used since significantly decreased the frequency of exacerbations and increased the time to first ...

Highly symptomatic bronchiectasis patients have increased exacerbation risks, regardless of previous exacerbation history or disease severity. Current guidelines do not recommend preventive treatments ...

Panelists discuss how reducing bronchiectasis exacerbations requires standardized definitions, tailored antibiotic approaches, and increased airway clearance, while addressing underlying conditions ...

Please provide your email address to receive an email when new articles are posted on . The relationship between blood eosinophil count and bronchiectasis severity was U-shaped, meaning greater ...

Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 10 mg or 25 mg performed better than placebo for three outcomes related to pulmonary ...

Treatment with the novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor brensocatib prolonged time to first exacerbation for patients with non-cystic fibrosis bronchiectasis, and led to fewer ...

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...

The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

BRIDGEWATER, N.J., Sept. 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...